What is the appropriate evaluation and treatment for low serum phosphate in a child?

Evaluation and Treatment of Low Serum Phosphate in Children

For a child with confirmed hypophosphatemia, first determine if this is X-linked hypophosphatemia (XLH) or another cause, then initiate burosumab as first-line therapy for children ≥12 months with XLH, or use conventional therapy (oral phosphate plus active vitamin D) if burosumab is unavailable or for non-XLH causes.

Initial Diagnostic Evaluation

When encountering low serum phosphate in a pediatric patient, obtain the following workup:

• Fasting serum phosphate (morning sample, 2-3 hour fast) with age-appropriate reference ranges
• Alkaline phosphatase (ALP) - persistently low ALP suggests hypophosphatasia (HPP), while elevated ALP suggests rickets
• Parathyroid hormone (PTH)
• 25-hydroxyvitamin D levels
• Serum calcium and creatinine
• Simultaneous urine phosphate and creatinine (within 2 hours of serum collection) to calculate tubular reabsorption of phosphate
• Renal ultrasound to screen for nephrocalcinosis
• Skeletal radiographs (knee/wrist) to assess for rickets if clinically indicated 1

Critical distinction: Low ALP with hypophosphatemia indicates hypophosphatasia (HPP), not rickets. These patients require asfotase alfa (enzyme replacement), not phosphate supplementation 2, 3.

Treatment for X-Linked Hypophosphatemia (XLH)

First-Line: Burosumab Therapy

For children ≥12 months with XLH, burosumab is strongly recommended over conventional therapy (strong recommendation, moderate certainty) 1. For infants 6-12 months, burosumab is conditionally recommended over conventional therapy 1.

Burosumab dosing strategy:

• Adhere to recommended starting doses based on product labeling
• Adjust doses to achieve serum phosphorus in the low- to mid-normal range (peak) or just below normal (trough) for age
• Dose adjustments should be based on optimizing serum phosphorus levels, not solely weight increases, to avoid hyperphosphatemia 1
• Do NOT routinely measure FGF23 levels for monitoring 4

Alternative: Conventional Therapy

If burosumab is unavailable, use oral phosphate salts combined with active vitamin D - this is preferred over no treatment 1.

Phosphate supplementation:

• Initial dose: 20-60 mg elemental phosphorus/kg/day in infants and preschool children 4
• Frequency: 4-6 times daily in young patients with high ALP; reduce to 3-4 times daily when ALP normalizes 4
• Maximum dose: Do not exceed 60-80 mg/kg/day to prevent gastrointestinal discomfort and hyperparathyroidism 4, 1
• Never use phosphate salts as monotherapy - always combine with active vitamin D 1

Active vitamin D dosing:

• Calcitriol: 20-30 ng/kg/day (or start empirically at 0.5 μg daily in children >12 months)
• Alfacalcidol: 30-50 ng/kg/day (or start empirically at 1 μg daily in children >12 months) 4
• Calcitriol is typically given twice daily; alfacalcidol once daily due to longer half-life 1

Critical pitfall: Avoid targeting normal fasting serum phosphorus levels with conventional therapy to prevent phosphate overdosing and toxicity 1. Instead, aim to normalize ALP and promote normal growth.

Monitoring Parameters

Essential monitoring (every 3-6 months):

• Serum phosphate, calcium, ALP, PTH, creatinine
• Urinary calcium excretion - keep within normal range to prevent nephrocalcinosis 4
• Growth parameters and clinical signs of rickets
• Annual renal ultrasound for nephrocalcinosis screening 1
• 25-hydroxyvitamin D at least annually 1

Dose adjustments:

• If persistent hypercalciuria develops: Decrease active vitamin D dose, ensure adequate hydration, consider potassium citrate, limit sodium intake 4
• If hyperparathyroidism develops: This indicates unbalanced phosphate increases without adequate active vitamin D - increase vitamin D dose rather than decreasing phosphate 4, 1
• If immobilized >1 week: Decrease or stop active vitamin D; restart when ambulating 4

Key Clinical Pitfalls

1. Do not confuse hypophosphatasia (HPP) with hypophosphatemic rickets - HPP has LOW alkaline phosphatase and requires asfotase alfa, not phosphate supplementation 2, 3

2. Commence treatment promptly upon diagnosis - early intervention optimizes outcomes for growth, skeletal development, and long-term function 1

3. With conventional therapy, unbalanced phosphate increases without adequate vitamin D leads to secondary hyperparathyroidism - always adjust both medications together 4, 1

4. Phosphate monotherapy is contraindicated - it worsens hyperparathyroidism and outcomes 1

5. Regular dental care is essential - children with XLH require dental visits every 6-12 months after tooth eruption to prevent and treat dental abscesses 1